Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
Clinical trial NCT03916185 · TERMINATED
Trial details
- NCT number
- NCT03916185
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-20
- Primary completion
- 2024-01-22
- Enrollment
- 67
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.